Kissei Pharmaceutical Co Ltd - Product Pipeline Review - 2016

Published: Dec, 2016 | Pages: 57 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Kissei Pharmaceutical Co Ltd - Product Pipeline Review - 2016

Summary

Global Markets Direct's, 'Kissei Pharmaceutical Co Ltd - Product Pipeline Review - 2016', provides an overview of the Kissei Pharmaceutical Co Ltd's pharmaceutical research and development focus. 

The report provides comprehensive information on the therapeutics under development by Kissei Pharmaceutical Co Ltd, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Kissei Pharmaceutical Co Ltd
- The report provides overview of Kissei Pharmaceutical Co Ltd including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report assesses Kissei Pharmaceutical Co Ltd's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report features Kissei Pharmaceutical Co Ltd's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons To Buy

- Evaluate Kissei Pharmaceutical Co Ltd's strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Kissei Pharmaceutical Co Ltd
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Kissei Pharmaceutical Co Ltd's pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Kissei Pharmaceutical Co Ltd Snapshot 7
Kissei Pharmaceutical Co Ltd Overview 7
Key Facts 7
Kissei Pharmaceutical Co Ltd - Research and Development Overview 8
Key Therapeutic Areas 8
Kissei Pharmaceutical Co Ltd - Pipeline Review 11
Pipeline Products by Stage of Development 11
Pipeline Products - Monotherapy 12
Pipeline Products - Partnered Products 13
Partnered Products/Combination Treatment Modalities 14
Pipeline Products - Out-Licensed Products 15
Out-Licensed Products/Combination Treatment Modalities 16
Kissei Pharmaceutical Co Ltd - Pipeline Products Glance 17
Kissei Pharmaceutical Co Ltd - Late Stage Pipeline Products 17
Pre-Registration Products/Combination Treatment Modalities 17
Phase III Products/Combination Treatment Modalities 18
Kissei Pharmaceutical Co Ltd - Clinical Stage Pipeline Products 19
Phase II Products/Combination Treatment Modalities 19
Phase I Products/Combination Treatment Modalities 20
Kissei Pharmaceutical Co Ltd - Early Stage Pipeline Products 21
Preclinical Products/Combination Treatment Modalities 21
Kissei Pharmaceutical Co Ltd - Drug Profiles 22
AS-192426900 - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
AS-192781900 - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
AS-193280400 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
bedoradrine sulfate - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
KDT-3594 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
KLH-2109 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
KSI-6666 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
KTA-439 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
mitiglinide - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
ozagrel - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
remogliflozin etabonate - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
rovatirelin - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Small Molecule to Inhibit SGLT1 for Postprandial Hyperglycemia - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
YS-110 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Kissei Pharmaceutical Co Ltd - Pipeline Analysis 44
Kissei Pharmaceutical Co Ltd - Pipeline Products by Target 44
Kissei Pharmaceutical Co Ltd - Pipeline Products by Route of Administration 46
Kissei Pharmaceutical Co Ltd - Pipeline Products by Molecule Type 47
Kissei Pharmaceutical Co Ltd - Pipeline Products by Mechanism of Action 48
Kissei Pharmaceutical Co Ltd - Dormant Projects 50
Kissei Pharmaceutical Co Ltd - Discontinued Pipeline Products 51
Discontinued Pipeline Product Profiles 52
diquafosol tetrasodium 52
KEA-0477 52
KGA-3235 52
KLS-0611 52
KUX-1151 52
neflamapimod 52
remogliflozin etabonate 52
ritobegron 52
sergliflozin 53
Kissei Pharmaceutical Co Ltd - Company Statement 54
Kissei Pharmaceutical Co Ltd - Locations And Subsidiaries 55
Head Office 55
Other Locations & Subsidiaries 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57

List of Tables

Kissei Pharmaceutical Co Ltd, Key Facts 7
Kissei Pharmaceutical Co Ltd - Pipeline by Indication, 2016 10
Kissei Pharmaceutical Co Ltd - Pipeline by Stage of Development, 2016 11
Kissei Pharmaceutical Co Ltd - Monotherapy Products in Pipeline, 2016 12
Kissei Pharmaceutical Co Ltd - Partnered Products in Pipeline, 2016 13
Kissei Pharmaceutical Co Ltd - Partnered Products/ Combination Treatment Modalities, 2016 14
Kissei Pharmaceutical Co Ltd - Out-Licensed Products in Pipeline, 2016 15
Kissei Pharmaceutical Co Ltd - Out-Licensed Products/ Combination Treatment Modalities, 2016 16
Kissei Pharmaceutical Co Ltd - Pre-Registration, 2016 17
Kissei Pharmaceutical Co Ltd - Phase III, 2016 18
Kissei Pharmaceutical Co Ltd - Phase II, 2016 19
Kissei Pharmaceutical Co Ltd - Phase I, 2016 20
Kissei Pharmaceutical Co Ltd - Preclinical, 2016 21
Kissei Pharmaceutical Co Ltd - Pipeline by Target, 2016 45
Kissei Pharmaceutical Co Ltd - Pipeline by Route of Administration, 2016 46
Kissei Pharmaceutical Co Ltd - Pipeline by Molecule Type, 2016 47
Kissei Pharmaceutical Co Ltd - Pipeline Products by Mechanism of Action, 2016 49
Kissei Pharmaceutical Co Ltd - Dormant Developmental Projects,2016 50
Kissei Pharmaceutical Co Ltd - Discontinued Pipeline Products, 2016 51
Kissei Pharmaceutical Co Ltd, Other Locations 55
Kissei Pharmaceutical Co Ltd, Subsidiaries 55